Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.49 |
| ▸ | PDE5A | O76074 | 4/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204912 | 0.88 | PDE5A (0.56) | PDE3BPDE3APDE5APDE2ADHODH | |
| SCHEMBL2208752 | 0.86 | PDE5A (0.57) | PDE3BPDE3APDE5APDE2ADHODH | |
| SCHEMBL2203773 | 0.85 | PDE3B (0.55) | PDE3BPDE3APDE5APDE2ADHODH | |
| SCHEMBL2207950 | 0.85 | PDE3B (0.54) | PDE3BPDE3APDE5APDE2ADHODH | |
| SCHEMBL6318214 | 0.84 | PDE3B (0.68) | PDE3BPDE3APDE5AGPR119PDE2A | |
| SCHEMBL2205488 | 0.83 | PDE3B (0.54) | PDE3BPDE3APDE5APDE2ADHODH | |
| SCHEMBL2204308 | 0.83 | PDE5A (0.57) | PDE3BPDE3APDE5APDE2ADHODH | |
| SCHEMBL2206095 | 0.82 | PDE5A (0.51) | PDE3BPDE3APDE5APDE2ADHODH | |
| SCHEMBL2201810 | 0.81 | PDE5A (0.53) | PDE3BPDE3APDE5APDE2ADHODH | |
| SCHEMBL2205223 | 0.81 | PDE3B (0.52) | PDE3BPDE3APDE5APDE2ADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230468-A1 | FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-22 | — | — | US | claimed |
| US-20110230468-A1 | FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-22 | — | — | US | disclosed |
| US-7981881-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981881-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-20080293650-A1 | Fused Heterocyclic Compounds and Use Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
| US-20080293650-A1 | Fused Heterocyclic Compounds and Use Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
| US-7384937-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384937-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20040142945-A1 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004043367-A2 | FUSED HETEROCYCLIC COMPOUNDS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230468-A1 | FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF | MCL1, FPR1, LTC4S | PDE3B 3256/4885PDE3A 3666/4885PDE5A 3946/4885 |
| US-20040142945-A1 | Fused heterocyclic compounds and use thereof | MCL1, NFATC1, BCR | PDE3B 3374/4885PDE3A 3722/4885PDE5A 3715/4885 |
| US-20080293650-A1 | Fused Heterocyclic Compounds and Use Thereof | MCL1, FPR1, LTB4R | PDE3B 3217/4885PDE3A 3655/4885PDE5A 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.